These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 24608575)

  • 1. Enhancement of nab-paclitaxel antitumor activity through addition of multitargeting antiangiogenic agents in experimental pancreatic cancer.
    Awasthi N; Zhang C; Schwarz AM; Hinz S; Schwarz MA; Schwarz RE
    Mol Cancer Ther; 2014 May; 13(5):1032-43. PubMed ID: 24608575
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of poly-mechanistic antiangiogenic combinations to enhance cytotoxic therapy response in pancreatic cancer.
    Awasthi N; Zhang C; Ruan W; Schwarz MA; Schwarz RE
    PLoS One; 2012; 7(6):e38477. PubMed ID: 22723862
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Augmentation of response to nab-paclitaxel by inhibition of insulin-like growth factor (IGF) signaling in preclinical pancreatic cancer models.
    Awasthi N; Scire E; Monahan S; Grojean M; Zhang E; Schwarz MA; Schwarz RE
    Oncotarget; 2016 Jul; 7(30):46988-47001. PubMed ID: 27127884
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparative benefits of Nab-paclitaxel over gemcitabine or polysorbate-based docetaxel in experimental pancreatic cancer.
    Awasthi N; Zhang C; Schwarz AM; Hinz S; Wang C; Williams NS; Schwarz MA; Schwarz RE
    Carcinogenesis; 2013 Oct; 34(10):2361-9. PubMed ID: 23803690
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dual inhibition of the PI3K and MAPK pathways enhances nab-paclitaxel/gemcitabine chemotherapy response in preclinical models of pancreatic cancer.
    Awasthi N; Kronenberger D; Stefaniak A; Hassan MS; von Holzen U; Schwarz MA; Schwarz RE
    Cancer Lett; 2019 Sep; 459():41-49. PubMed ID: 31153980
    [TBL] [Abstract][Full Text] [Related]  

  • 6. EMAP II-based antiangiogenic-antiendothelial in vivo combination therapy of pancreatic cancer.
    Schwarz RE; Awasthi N; Konduri S; Cafasso D; Schwarz MA
    Ann Surg Oncol; 2010 May; 17(5):1442-52. PubMed ID: 20041350
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antitumour activity of sunitinib in combination with gemcitabine in experimental pancreatic cancer.
    Awasthi N; Schwarz MA; Schwarz RE
    HPB (Oxford); 2011 Sep; 13(9):597-604. PubMed ID: 21843259
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Therapeutic efficacy of anti-MMP9 antibody in combination with nab-paclitaxel-based chemotherapy in pre-clinical models of pancreatic cancer.
    Awasthi N; Mikels-Vigdal AJ; Stefanutti E; Schwarz MA; Monahan S; Smith V; Schwarz RE
    J Cell Mol Med; 2019 Jun; 23(6):3878-3887. PubMed ID: 30941918
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Augmentation of
    Awasthi N; Schwarz MA; Zhang C; Schwarz RE
    Mol Cancer Ther; 2018 Nov; 17(11):2353-2364. PubMed ID: 30166402
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bisphosphonates inhibit stellate cell activity and enhance antitumor effects of nanoparticle albumin-bound paclitaxel in pancreatic ductal adenocarcinoma.
    Gonzalez-Villasana V; Rodriguez-Aguayo C; Arumugam T; Cruz-Monserrate Z; Fuentes-Mattei E; Deng D; Hwang RF; Wang H; Ivan C; Garza RJ; Cohen E; Gao H; Armaiz-Pena GN; Del C Monroig-Bosque P; Philip B; Rashed MH; Aslan B; Erdogan MA; Gutierrez-Puente Y; Ozpolat B; Reuben JM; Sood AK; Logsdon C; Lopez-Berestein G
    Mol Cancer Ther; 2014 Nov; 13(11):2583-94. PubMed ID: 25193509
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The dual PI3K/mTOR inhibitor NVP-BEZ235 enhances nab-paclitaxel antitumor response in experimental gastric cancer.
    Zhang CΗ; Awasthi N; Schwarz MA; Schwarz RE
    Int J Oncol; 2013 Nov; 43(5):1627-35. PubMed ID: 24042258
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The effect of paclitaxel and nab-paclitaxel in combination with anti-angiogenic therapy in breast cancer cell lines.
    Tonissi F; Lattanzio L; Merlano MC; Infante L; Lo Nigro C; Garrone O
    Invest New Drugs; 2015 Aug; 33(4):801-9. PubMed ID: 25947567
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibition of the MEK/ERK pathway augments nab-paclitaxel-based chemotherapy effects in preclinical models of pancreatic cancer.
    Awasthi N; Monahan S; Stefaniak A; Schwarz MA; Schwarz RE
    Oncotarget; 2018 Jan; 9(4):5274-5286. PubMed ID: 29435178
    [TBL] [Abstract][Full Text] [Related]  

  • 14. S-1 plus nab-paclitaxel is a promising regimen for pancreatic cancer in a preclinical model.
    Suenaga M; Yamada S; Fujii T; Tanaka C; Kanda M; Nakayama G; Sugimoto H; Koike M; Fujiwara M; Kodera Y
    J Surg Oncol; 2016 Mar; 113(4):413-9. PubMed ID: 27100026
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combretastatin-A4 phosphate improves the distribution and antitumor efficacy of albumin-bound paclitaxel in W256 breast carcinoma model.
    Gao M; Zhang D; Jin Q; Jiang C; Wang C; Li J; Peng F; Huang D; Zhang J; Song S
    Oncotarget; 2016 Sep; 7(36):58133-58141. PubMed ID: 27531898
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeted dual inhibition of c-Met/VEGFR2 signalling by foretinib improves antitumour effects of nanoparticle paclitaxel in gastric cancer models.
    Grojean M; Schwarz MA; Schwarz JR; Hassan S; von Holzen U; Zhang C; Schwarz RE; Awasthi N
    J Cell Mol Med; 2021 Jun; 25(11):4950-4961. PubMed ID: 33939252
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Superior antitumor activity of nanoparticle albumin-bound paclitaxel in experimental gastric cancer.
    Zhang C; Awasthi N; Schwarz MA; Hinz S; Schwarz RE
    PLoS One; 2013; 8(2):e58037. PubMed ID: 23460921
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Macropinocytosis of Nab-paclitaxel Drives Macrophage Activation in Pancreatic Cancer.
    Cullis J; Siolas D; Avanzi A; Barui S; Maitra A; Bar-Sagi D
    Cancer Immunol Res; 2017 Mar; 5(3):182-190. PubMed ID: 28108630
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Improved anticancer effects of albumin-bound paclitaxel nanoparticle via augmentation of EPR effect and albumin-protein interactions using S-nitrosated human serum albumin dimer.
    Kinoshita R; Ishima Y; Chuang VTG; Nakamura H; Fang J; Watanabe H; Shimizu T; Okuhira K; Ishida T; Maeda H; Otagiri M; Maruyama T
    Biomaterials; 2017 Sep; 140():162-169. PubMed ID: 28651144
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CEP-7055: a novel, orally active pan inhibitor of vascular endothelial growth factor receptor tyrosine kinases with potent antiangiogenic activity and antitumor efficacy in preclinical models.
    Ruggeri B; Singh J; Gingrich D; Angeles T; Albom M; Yang S; Chang H; Robinson C; Hunter K; Dobrzanski P; Jones-Bolin S; Pritchard S; Aimone L; Klein-Szanto A; Herbert JM; Bono F; Schaeffer P; Casellas P; Bourie B; Pili R; Isaacs J; Ator M; Hudkins R; Vaught J; Mallamo J; Dionne C
    Cancer Res; 2003 Sep; 63(18):5978-91. PubMed ID: 14522925
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.